杭州浙大迪迅生物基因工程有限公司Release date：2018-12-20
JACI:
DOI: https://doi.org/10.1016/j.jaci.2017.12.773
Abstract:
Rationale
Prior studies indicate that hazelnut component testing (HCT) may serve as a better indicator for clinical reactivity than skin prick (SPT) and hazelnut-specific IgE testing (hIgE) in patients with birch pollen allergy. The efficacy of HCT in determining clinical reactivity represents a potential gap in clinical management.
Methods
A retrospective chart review was performed on six patients who underwent HCT to Cor a 1, 8, 9, and 14. None of the patients ate products containing hazelnut (PCH) at the time of HCT due to prior positive allergy testing with hIgE testing (one patient had positive SPT). Four of the patients reported tolerating PCH prior to allergy testing, one had no exposures, and one developed throat itching upon ingestion. The charts were reviewed for demographic data, birch specific IgE (bIgE), hIgE levels, SPT test results, hazelnut Cor a 1, 8, 9, and 14 levels, and trial of PCH.
Results
Average total IgE=411.11 (SD: 529.07; N: 6), hIgE=15.95 (SD=17.36; N=6), bIGE=9.57 (SD=45.06; N=6), Cor a 1=29.85 (SD=40.16; N=6), Cor a 8=0.1 (SD=1.52; N=6), Cor a 9=0.34 (SD=0.53; N=6), and Cor a 14=0.27 (SD=0.27; N=6). Five of six patients introduced PCH into their diet. Their average Cor a 1=35.80 (SD=41.84; N=5) and Cor a 9=0.12 (SD=0.06; N=5) versus the one patient who did not introduce PCH (Cor a 1=0.1 and Cor a 9=1.43).
Conclusions
This was a pilot study undertaken to investigate the utility of HCT. This study suggests that HCT can determine clinical reactivity in birch pollen allergic patients with positive hIgE.
All Author:
Joel P. Brooks, DO, Francis M. Lobo, MD
[IF:13.1]
The Efficacy of Hazelnut IgE Component Testing in Determining Hazelnut SensitivityDOI: https://doi.org/10.1016/j.jaci.2017.12.773
Abstract:
Rationale
Prior studies indicate that hazelnut component testing (HCT) may serve as a better indicator for clinical reactivity than skin prick (SPT) and hazelnut-specific IgE testing (hIgE) in patients with birch pollen allergy. The efficacy of HCT in determining clinical reactivity represents a potential gap in clinical management.
Methods
A retrospective chart review was performed on six patients who underwent HCT to Cor a 1, 8, 9, and 14. None of the patients ate products containing hazelnut (PCH) at the time of HCT due to prior positive allergy testing with hIgE testing (one patient had positive SPT). Four of the patients reported tolerating PCH prior to allergy testing, one had no exposures, and one developed throat itching upon ingestion. The charts were reviewed for demographic data, birch specific IgE (bIgE), hIgE levels, SPT test results, hazelnut Cor a 1, 8, 9, and 14 levels, and trial of PCH.
Results
Average total IgE=411.11 (SD: 529.07; N: 6), hIgE=15.95 (SD=17.36; N=6), bIGE=9.57 (SD=45.06; N=6), Cor a 1=29.85 (SD=40.16; N=6), Cor a 8=0.1 (SD=1.52; N=6), Cor a 9=0.34 (SD=0.53; N=6), and Cor a 14=0.27 (SD=0.27; N=6). Five of six patients introduced PCH into their diet. Their average Cor a 1=35.80 (SD=41.84; N=5) and Cor a 9=0.12 (SD=0.06; N=5) versus the one patient who did not introduce PCH (Cor a 1=0.1 and Cor a 9=1.43).
Conclusions
This was a pilot study undertaken to investigate the utility of HCT. This study suggests that HCT can determine clinical reactivity in birch pollen allergic patients with positive hIgE.
All Author:
Joel P. Brooks, DO, Francis M. Lobo, MD
2018-12-16 Article
Hangzhou Zheda Dixun Biological Gene Engineering Co., Ltd. Copyright HZKC Technical support 浙ICP备14005341号 （浙）-非经营性-2019-0050
Address: Rm.201-209, Bldg.2, No.568 Binkang Rd., Binjiang Dist. Tel: 0571-87968248-805 Website:www.zdbiogene.com
COPYRIGHT©2003-2024 www.zdbiogene.com CORPORATION. ALL RIGHTS RESERVED
Official WeChat